

---

## Notice of Upcoming Investor Call – First Half FY21 Results

**Adelaide, Australia, 18 February 2021** – Nova Eye Medical Limited (ASX: EYE)(Nova Eye Medical or the Company), a medical technology company committed to advanced ophthalmic treatment technologies and devices, today advises that following the release of the Appendix 4D Half Year Financial Results to 31 December 2020, the Company will host an investor conference call at 9.30am AEDT (9.00am ACDT, Adelaide time) on Thursday, 25 February 2021 with Mr. Tom Spurling, Director of Nova Eye Medical.

Details of the call are set out below.

In order to pre-register for the conference call and avoid a queue when calling, please follow the link below. You will be given a unique pin number to enter when you call which will bypass the operator and give you immediate access to the event. Investors are advised to register for the conference in advance by using the Diamond Pass link to avoid delays in joining the call directly through the operator:

<https://s1.c-conf.com/diamondpass/10012344-msg724.html>

Alternatively, you may dial in with the following details, approximately ten minutes before the scheduled start time and provide the Conference ID to an operator.

Conference ID: **10012344**

Participant Dial-in Numbers:

Australia Toll Free: 1800 908299

Australia Local: +61 2 9007 8048

New Zealand: 0800 452 795

Canada/USA: 1855 624 0077

Hong Kong: 800 968 273

Japan: 006 633 868 000

China: 108 001 401 776

Singapore: 800 101 2702

United Kingdom: 0800 0511 453

The presentation and audio can also be accessed via the webcast link:

<https://services.choruscall.com.au/webcast/novaeye-210225.html>

***This release dated 18 February 2021 has been authorised for lodgement to ASX by the Board of Directors of Nova Eye Medical Limited and lodged by Simon Gray, Company Secretary.***

**– ENDS –**

**Company**

Tom Spurling  
Director  
Nova Eye Medical Limited  
W +61 417 818 658  
[tspurling@nova-eye.com](mailto:tspurling@nova-eye.com)

**Investors**

Dr. Tom Duthy  
Investor Relations & Corporate Development  
Nova Eye Medical Limited  
W +61 402 493 727  
[tduthy@nova-eye.com](mailto:tduthy@nova-eye.com)

**Media**

Kate Hunt  
Head of Marketing  
Nova Eye Medical Limited  
W +61 404 080 679  
[khunt@nova-eye.com](mailto:khunt@nova-eye.com)

---

**ABOUT NOVA EYE MEDICAL**

Nova Eye Medical Limited is a medical technology company that develops, manufactures and sells a portfolio of proprietary ophthalmic treatment technologies and devices. Used by eye surgeons in more than 100 countries globally, these technologies include iTrack™ minimally invasive glaucoma surgery (MIGS), a consumable surgical device that restores the eye's natural outflow pathway to lower pressure inside the eye and to eliminate patient reliance on anti-glaucoma medications for mild-moderate glaucoma. The Molteno3® glaucoma drainage device platform is designed to enhance surgical utility and optimize clinical outcomes for long-term IOP control in cases of severe glaucoma. It also offers the benefit of a simplified and faster surgical procedure. With its sales headquarters based in Fremont, California, Nova Eye Medical is supported by a global network of more than 50 distribution partners. Manufacturing facilities are located in Fremont, California and Dunedin, New Zealand.

For additional information about Nova Eye Medical and its technologies, please visit: [www.nova-eye.com](http://www.nova-eye.com)

---